1. [CASE 1 — QUESTION 1]
A 64-year-old man is admitted to the intensive care unit with septic shock from a urinary source. He has received 30 milliliters per kilogram of balanced crystalloid and broad-spectrum antibiotics, yet remains hypotensive and now requires a norepinephrine infusion exceeding 0.25 micrograms per kilogram per minute, with the requirement escalating over the past hour. Lactate remains elevated. Which adjunctive pharmacological intervention is most appropriate at this point?
A) Begin high-dose dexamethasone, the preferred glucocorticoid for shock reversal
B) Withhold any glucocorticoid until a short ACTH (adrenocorticotropic hormone) stimulation test confirms a responder subgroup
C) Add low-dose hydrocortisone, approximately 200 milligrams per day by continuous infusion or in divided doses
D) Discontinue norepinephrine and rely on a glucocorticoid alone to restore perfusion
E) Administer a single dose of inhaled corticosteroid
ANSWER: C
Rationale:
The synthesis of the major septic shock trials supports adding low-dose hydrocortisone, about 200 milligrams per day, for shock that remains refractory after adequate fluid resuscitation and requires high, escalating vasopressor support. This patient meets that threshold, making Option C correct.
Option A: Option A is incorrect because hydrocortisone, not dexamethasone, is the agent used in septic shock; dexamethasone lacks the mineralocorticoid activity relevant here, and its long duration complicates titration and discontinuation.
Option B: Option B is incorrect because the short ACTH stimulation test was found not to identify a benefiting subgroup and is not used to select patients for hydrocortisone.
Option D: Option D is incorrect because glucocorticoids are an adjunct and do not replace vasopressor support in septic shock.
Option E: Option E is incorrect because an inhaled corticosteroid has no role in the systemic management of septic shock.
2. [CASE 1 — QUESTION 2]
Continuing with the same patient, a trainee asks why hydrocortisone is preferred over dexamethasone in this setting. Which explanation is most accurate?
A) Hydrocortisone provides mineralocorticoid activity that supports vascular tone in shock, and its shorter duration allows easier titration and discontinuation as the shock resolves, whereas dexamethasone lacks meaningful mineralocorticoid activity and its long duration makes titration difficult
B) Dexamethasone is preferred in septic shock, and hydrocortisone is an inferior substitute used only when dexamethasone is unavailable
C) Hydrocortisone is chosen because it has no glucocorticoid activity and acts purely as a mineralocorticoid
D) The two agents are pharmacologically identical, so the choice is arbitrary
E) Hydrocortisone is preferred because it has a much longer duration of action than dexamethasone
ANSWER: A
Rationale:
Hydrocortisone, the synthetic equivalent of cortisol, carries mineralocorticoid as well as glucocorticoid activity, which helps support vascular tone in shock, and its relatively short duration permits easier titration and discontinuation as the patient improves. Dexamethasone lacks meaningful mineralocorticoid activity and its long duration complicates titration, so hydrocortisone is preferred. This makes Option A correct.
Option B: Option B is incorrect because hydrocortisone, not dexamethasone, is the preferred agent in septic shock.
Option C: Option C is incorrect because hydrocortisone has substantial glucocorticoid activity in addition to mineralocorticoid activity, not a purely mineralocorticoid action.
Option D: Option D is incorrect because the agents differ in mineralocorticoid activity and duration, so the choice is not arbitrary.
Option E: Option E is incorrect because hydrocortisone has a shorter, not longer, duration of action than dexamethasone.
3. [CASE 1 — QUESTION 3]
Continuing with the same patient, a short ACTH (adrenocorticotropic hormone) stimulation test is performed and shows a brisk cortisol response. How should this result guide the decision to use hydrocortisone?
A) A brisk response confirms the patient will not benefit and mandates withholding hydrocortisone
B) The test result should override the clinical picture and prompt immediate discontinuation of vasopressors
C) A brisk response indicates primary adrenal insufficiency requiring lifelong replacement
D) The test should be repeated daily to titrate the hydrocortisone dose
E) The stimulation test does not reliably identify who benefits, so the decision to give hydrocortisone rests on the clinical criterion of refractory shock despite fluids and escalating vasopressors rather than on the test result
ANSWER: E
Rationale:
A major septic shock trial specifically found that the response to a short ACTH stimulation test did not identify a subgroup who benefited from hydrocortisone. The decision therefore rests on the clinical criterion of refractory shock after adequate fluids and with high, escalating vasopressor requirements, not on the test result. This makes Option E correct.
Option A: Option A is incorrect because a brisk response does not establish absence of benefit, since the test does not discriminate responders.
Option B: Option B is incorrect because the test result should not override the clinical picture or prompt abrupt vasopressor discontinuation.
Option C: Option C is incorrect because a brisk cortisol response argues against, not for, primary adrenal insufficiency.
Option D: Option D is incorrect because the test is not used for daily dose titration in this setting.
4. [CASE 1 — QUESTION 4]
Continuing with the same patient, by hospital day 3 his vasopressor requirement has steadily declined and norepinephrine is nearly weaned off. How should the hydrocortisone be managed?
A) Continue hydrocortisone indefinitely at the same dose regardless of hemodynamic improvement
B) Plan to discontinue hydrocortisone as vasopressors are withdrawn, typically by the time of vasopressor discontinuation or by about 7 days, in line with the shock-driven indication
C) Abruptly increase the hydrocortisone dose now that the patient is improving
D) Switch to long-term dexamethasone for maintenance once shock resolves
E) Add fludrocortisone permanently as lifelong replacement
ANSWER: B
Rationale:
Hydrocortisone in septic shock is given for the duration of the refractory shock state; it is appropriate to discontinue it as vasopressors are withdrawn, generally by the time of vasopressor discontinuation or by about 7 days. As the indication resolves, so does the need for the drug, making Option B correct.
Option A: Option A is incorrect because indefinite continuation is not indicated once the shock-driven need has resolved.
Option C: Option C is incorrect because there is no rationale to escalate the dose during recovery.
Option D: Option D is incorrect because there is no role for long-term maintenance dexamethasone after septic shock resolves.
Option E: Option E is incorrect because lifelong fludrocortisone replacement is not indicated; this patient does not have primary adrenal insufficiency.
5. [CASE 2 — QUESTION 1]
A 41-year-old woman is two weeks out from a deceased-donor kidney transplant and is maintained on tacrolimus and prednisone. Her transplant nephrologist explains how the two drugs work together against rejection. Which description of their synergy is most accurate?
A) The calcineurin inhibitor blocks the calcineurin-NFAT (nuclear factor of activated T cells) pathway driving IL-2 (interleukin-2) gene transcription, while the glucocorticoid broadly suppresses T cell activation including IL-2 production and antigen presentation, so IL-2-dependent expansion of alloreactive T cells is inhibited at more than one level
B) Both drugs act at the identical calcineurin-NFAT step, simply doubling inhibition at one point
C) The glucocorticoid increases calcineurin activity, which the calcineurin inhibitor then blocks
D) The calcineurin inhibitor provides transrepression while the glucocorticoid directly inhibits calcineurin
E) Both agents act solely by inducing apoptosis of mature peripheral T cells
ANSWER: A
Rationale:
Calcineurin inhibitors block the calcineurin-NFAT pathway that drives IL-2 gene transcription, and glucocorticoids broadly suppress T cell activation, reducing IL-2 production and downregulating antigen presentation and costimulation. Because the two classes limit IL-2-dependent clonal expansion of alloreactive T cells at more than one level, the combination is synergistic, making Option A correct.
Option B: Option B is incorrect because the drugs act at different levels rather than the same calcineurin-NFAT step.
Option C: Option C is incorrect because glucocorticoids do not increase calcineurin activity.
Option D: Option D is incorrect because it reverses the mechanisms: the glucocorticoid provides transrepression and the calcineurin inhibitor blocks the calcineurin pathway.
Option E: Option E is incorrect because apoptosis of mature peripheral T cells is not the dominant shared mechanism in humans.
6. [CASE 2 — QUESTION 2]
Continuing with the same patient, suppose she had instead been maintained on cyclosporine rather than tacrolimus and received pulse methylprednisolone for a rejection episode. Which pharmacokinetic interaction should be anticipated?
A) Cyclosporine induces CYP3A4 (cytochrome P450 3A4), lowering methylprednisolone exposure
B) Cyclosporine has no effect on methylprednisolone metabolism
C) Cyclosporine accelerates renal excretion of methylprednisolone
D) Cyclosporine inhibits CYP3A4, which can moderately increase methylprednisolone exposure and warrants monitoring for glucocorticoid excess
E) Cyclosporine converts methylprednisolone into an inactive metabolite, reducing its effect
ANSWER: D
Rationale:
Cyclosporine inhibits CYP3A4, the enzyme that metabolizes methylprednisolone, so co-administration can moderately increase methylprednisolone exposure, warranting attention to signs of glucocorticoid excess. This makes Option D correct.
Option A: Option A is incorrect because cyclosporine inhibits rather than induces CYP3A4, so exposure rises rather than falls.
Option B: Option B is incorrect because the interaction is pharmacokinetically meaningful, not absent.
Option C: Option C is incorrect because the interaction is metabolic inhibition, not accelerated renal excretion.
Option E: Option E is incorrect because cyclosporine does not convert methylprednisolone into an inactive metabolite; it slows its metabolism.
7. [CASE 2 — QUESTION 3]
Continuing with the same patient, several months later she is diagnosed with active tuberculosis and rifampin is added to her regimen. Which consequence should the transplant team most anticipate and monitor for?
A) Rifampin will raise glucocorticoid and calcineurin inhibitor levels, causing drug toxicity
B) Rifampin induces CYP3A4, lowering levels of both the glucocorticoid and the calcineurin inhibitor and thereby raising the risk of acute rejection, so drug levels and allograft function should be monitored closely
C) Rifampin has no metabolic interaction with immunosuppressants
E) Rifampin blocks renal clearance of tacrolimus, producing accumulation
ANSWER: B
Rationale:
Rifampin is a potent CYP3A4 inducer, and both the glucocorticoid and the calcineurin inhibitor are CYP3A4 substrates. Induction lowers their concentrations and can drop immunosuppression below the protective threshold, raising the risk of acute rejection, so close monitoring of drug levels and graft function is required. This makes Option B correct.
Option A: Option A is incorrect because induction lowers, rather than raises, immunosuppressant levels.
Option C: Option C is incorrect because the induction interaction is clinically significant rather than absent.
Option D: Option D is incorrect because rifampin lowers glucocorticoid exposure rather than increasing receptor expression.
Option E: Option E is incorrect because the interaction is metabolic induction, not blockade of renal clearance.
8. [CASE 2 — QUESTION 4]
Continuing with the same patient, her transplant center practices steroid-minimization for low-immunological-risk recipients. What is the rationale for tapering prednisone to discontinuation within months of transplant in selected patients?
A) Steroid minimization is done because glucocorticoids provide no immunosuppressive benefit in transplantation
B) It is done because chronic prednisone increases the risk of acute rejection
C) It is required because glucocorticoids interfere with calcineurin inhibitor absorption
D) It is done solely to lower medication costs, with no pharmacological rationale
E) It reduces the long-term burden of glucocorticoid adverse effects without substantially increasing rejection risk in appropriately selected low-risk recipients, who can be maintained on other immunosuppressants
ANSWER: E
Rationale:
Steroid-minimization protocols taper prednisone toward discontinuation within months in low-immunological-risk recipients to reduce the long-term adverse-effect burden of chronic glucocorticoids, while maintenance immunosuppression with other agents keeps rejection risk from rising substantially in appropriately selected patients. This makes Option E correct.
Option A: Option A is incorrect because glucocorticoids do contribute meaningful immunosuppression; minimization balances benefit against toxicity rather than denying benefit.
Option B: Option B is incorrect because chronic prednisone is not minimized because it raises rejection risk; minimization is feasible precisely because risk does not rise substantially in selected patients.
Option C: Option C is incorrect because the rationale is adverse-effect reduction, not an absorption interaction with the calcineurin inhibitor.
Option D: Option D is incorrect because the rationale is pharmacological and clinical rather than purely financial.
9. [CASE 3 — QUESTION 1]
A 72-year-old woman presents with two weeks of new temporal headache, scalp tenderness, and jaw claudication, and reports a transient episode of visual loss in the right eye this morning. Erythrocyte sedimentation rate and C-reactive protein are markedly elevated. Which intervention is most appropriate now?
A) Arrange an outpatient temporal artery biopsy and start low-dose prednisone 15 milligrams per day only after the result returns
B) Begin an inhaled corticosteroid and refer urgently to ophthalmology
C) Apply a topical ophthalmic corticosteroid to the affected eye
D) Initiate intravenous methylprednisolone pulse therapy immediately, before temporal artery biopsy, to prevent irreversible vision loss
E) Withhold all glucocorticoids until biopsy confirms giant cell arteritis
ANSWER: D
Rationale:
This is giant cell arteritis with visual involvement, an emergency in which delay risks permanent blindness from anterior ischemic optic neuropathy. The correct action is to start high-dose intravenous methylprednisolone pulse therapy immediately, before biopsy, because biopsy can still demonstrate vasculitis after glucocorticoids are begun and treatment must not wait. This makes Option D correct.
Option A: Option A is incorrect because deferring treatment for an outpatient biopsy and using only low-dose prednisone is unsafe when vision is threatened.
Option B: Option B is incorrect because inhaled corticosteroids provide no meaningful systemic coverage for large-vessel vasculitis.
Option C: Option C is incorrect because a topical ophthalmic corticosteroid does not treat the underlying systemic arteritis.
Option E: Option E is incorrect because withholding glucocorticoids until biopsy confirmation forfeits the narrow window in which vision can be preserved.
10. [CASE 3 — QUESTION 2]
Continuing with the same patient, the team explains why prompt high-dose therapy is so urgent. What is the principal mechanism of permanent vision loss in giant cell arteritis?
A) Retinal detachment from elevated intraocular pressure
B) Optic nerve compression by an orbital mass
C) Anterior ischemic optic neuropathy from inflammatory occlusion of the arteries supplying the optic nerve head, which can produce irreversible blindness if untreated
D) Cataract formation accelerated by inflammation
E) Corneal edema from cytokine release
ANSWER: C
Rationale:
In giant cell arteritis, vision loss results from anterior ischemic optic neuropathy: inflammatory involvement and occlusion of the arteries supplying the optic nerve head produces ischemia that can cause irreversible blindness if not treated rapidly, which is why even a short delay is dangerous. This makes Option C correct.
Option A: Option A is incorrect because the mechanism is arteritic ischemia of the optic nerve head, not retinal detachment from raised intraocular pressure.
Option B: Option B is incorrect because the problem is vascular inflammation, not compression by an orbital mass.
Option D: Option D is incorrect because cataract is not the cause of the acute vision threat in giant cell arteritis.
Option E: Option E is incorrect because corneal edema is not the mechanism of the ischemic vision loss in this disease.
11. [CASE 3 — QUESTION 3]
Continuing with the same patient, she stabilizes on high-dose prednisone but has poorly controlled diabetes and the team wishes to limit cumulative glucocorticoid exposure. Which adjunctive agent is approved to allow a more rapid prednisone taper with lower relapse rates in giant cell arteritis?
A) Tocilizumab, an IL-6 (interleukin-6) receptor antagonist, which has been approved as adjunctive therapy in giant cell arteritis and permits a faster prednisone taper with lower relapse rates than prednisone alone
B) An inhaled corticosteroid added to reduce systemic prednisone needs
C) A topical superpotent corticosteroid over the temporal arteries
D) Fludrocortisone to reduce vasculitic inflammation
E) A calcineurin inhibitor as first-line monotherapy replacing prednisone entirely
ANSWER: A
Rationale:
Tocilizumab, an IL-6 receptor antagonist, has been approved as adjunctive therapy in giant cell arteritis and allows a more rapid prednisone taper with lower relapse rates compared with prednisone monotherapy, representing an effective steroid-sparing strategy that is valuable when glucocorticoid toxicity such as poorly controlled diabetes is a concern. This makes Option A correct.
Option B: Option B is incorrect because an inhaled corticosteroid does not provide systemic steroid-sparing coverage for vasculitis.
Option C: Option C is incorrect because a topical corticosteroid cannot treat large-vessel arteritis.
Option D: Option D is incorrect because fludrocortisone is a mineralocorticoid and is not a steroid-sparing anti-inflammatory agent in giant cell arteritis.
Option E: Option E is incorrect because a calcineurin inhibitor is not the approved first-line replacement for prednisone in this disease.
12. [CASE 3 — QUESTION 4]
Continuing with the same patient, she will require prolonged glucocorticoid therapy over many months. Applying the bone effects of glucocorticoids, which preventive consideration is most appropriate to address early?
A) No bone-protective measures are needed because glucocorticoids increase bone formation
B) Bone loss is a concern only after several years, so prophylaxis can be deferred indefinitely
C) Glucocorticoids affect only osteoclasts, so any osteoblast-directed concern is irrelevant
D) Bone turnover halts on therapy, so fracture risk does not rise
E) Glucocorticoids raise RANKL (receptor activator of nuclear factor kappa-B ligand) and lower OPG (osteoprotegerin) to favor resorption while suppressing osteoblast function and promoting osteoblast apoptosis, producing net bone loss, so early attention to glucocorticoid-induced osteoporosis prevention is warranted
ANSWER: E
Rationale:
Glucocorticoids increase RANKL and decrease OPG, favoring osteoclast-driven resorption, and simultaneously suppress osteoblast differentiation and promote osteoblast apoptosis, reducing formation. The combination produces net bone loss, so a patient facing prolonged high-dose therapy warrants early attention to glucocorticoid-induced osteoporosis prevention. This makes Option E correct.
Option A: Option A is incorrect because glucocorticoids reduce, not increase, bone formation.
Option B: Option B is incorrect because bone loss begins early in therapy, so prophylaxis should not be deferred indefinitely.
Option C: Option C is incorrect because both osteoclasts and osteoblasts are affected, so the osteoblast arm is clinically relevant.
Option D: Option D is incorrect because turnover is not halted; resorption is actively favored, raising fracture risk.
13. [CASE 4 — QUESTION 1]
A 58-year-old man with Crohn disease has taken prednisone 30 milligrams per day for the past 8 weeks and is scheduled for an elective bowel resection under general anesthesia. The anesthesiologist asks how to classify his risk for perioperative adrenal insufficiency. How should he be stratified and managed?
A) Minimal suppression — continue his usual dose with no additional coverage
B) Substantial HPA (hypothalamic-pituitary-adrenal) axis suppression presumed, because he takes more than 20 milligrams of prednisone per day for more than 3 weeks, so full stress-dose supplementation is warranted for this major procedure
C) No suppression — he should stop prednisone the morning of surgery
D) Suppression cannot be estimated without a stimulation test, so surgery must be delayed regardless
E) Partial suppression only, requiring no more than his usual oral dose
ANSWER: B
Rationale:
Patients taking more than 20 milligrams of prednisone per day for more than 3 weeks are presumed to have substantial HPA axis suppression and should receive full stress-dose supplementation for major procedures. This patient clearly meets that dose-duration threshold, making Option B correct.
Option A: Option A is incorrect because his dose and duration place him well above the minimal-suppression category.
Option C: Option C is incorrect because stopping prednisone the morning of surgery removes baseline coverage and increases crisis risk.
Option D: Option D is incorrect because the dose-duration history already establishes presumed suppression, so a stimulation test is not required and surgery need not be delayed solely for that reason.
Option E: Option E is incorrect because his exposure exceeds the partial-suppression range and warrants full stress-dose coverage, not merely his usual dose.
14. [CASE 4 — QUESTION 2]
Continuing with the same patient, on the first postoperative day he becomes hypotensive despite generous fluids and an escalating vasopressor infusion. The hemodynamic instability is out of proportion to documented blood loss, and laboratory studies show hyponatremia with a normal potassium. Which diagnosis best explains this picture?
A) Cardiogenic shock from perioperative myocardial infarction
B) Hypovolemic shock from unrecognized surgical hemorrhage
C) Anaphylaxis to a perioperative medication
D) Neurogenic shock from spinal anesthesia
E) Perioperative adrenal crisis from HPA (hypothalamic-pituitary-adrenal) axis suppression, indicated by fluid- and vasopressor-refractory hypotension disproportionate to blood loss, with hyponatremia and no hyperkalemia because the mineralocorticoid axis is preserved in secondary adrenal insufficiency
ANSWER: E
Rationale:
The combination of hypotension refractory to fluids and vasopressors, disproportionate to blood loss, with hyponatremia and a normal potassium in a chronically steroid-treated patient is the classic picture of perioperative adrenal crisis from a suppressed HPA axis; the preserved mineralocorticoid axis in secondary adrenal insufficiency explains the absent hyperkalemia. This makes Option E correct.
Option A: Option A is incorrect because the electrolyte pattern and disproportionate refractory hypotension point to adrenal crisis rather than primarily cardiogenic shock.
Option B: Option B is incorrect because the instability is out of proportion to documented blood loss, arguing against hemorrhage as the explanation.
Option C: Option C is incorrect because anaphylaxis would not produce this hyponatremia-without-hyperkalemia pattern and typically has other features.
Option D: Option D is incorrect because neurogenic shock does not explain the electrolyte findings or the chronic-steroid context.
15. [CASE 4 — QUESTION 3]
Continuing with the same patient, the team concludes that perioperative adrenal crisis is the most likely diagnosis. What is the most appropriate immediate treatment?
A) Withhold glucocorticoids until a random cortisol result returns
B) Administer high-dose dexamethasone as the preferred crisis agent
C) Give empiric intravenous hydrocortisone 100 milligrams immediately without waiting for cortisol testing, drawing a pre-dose random cortisol only if it will not delay treatment
D) Start oral fludrocortisone to correct the hyponatremia
E) Continue fluids and vasopressors alone and reassess in several hours
ANSWER: C
Rationale:
Suspected adrenal crisis is treated with empiric intravenous hydrocortisone 100 milligrams given immediately, without awaiting cortisol testing; a pre-dose random cortisol may be drawn for retrospective diagnosis only if it does not delay therapy. This makes Option C correct.
Option A: Option A is incorrect because delaying treatment for laboratory results risks a fatal but preventable crisis.
Option B: Option B is incorrect because hydrocortisone, not dexamethasone, is the conventional agent for acute crisis coverage.
Option D: Option D is incorrect because fludrocortisone is an oral mineralocorticoid for chronic replacement and does not treat the acute glucocorticoid-deficient crisis, which does not involve mineralocorticoid deficiency.
Option E: Option E is incorrect because continuing fluids and vasopressors alone ignores the specific, urgent need for glucocorticoid replacement.
16. [CASE 4 — QUESTION 4]
Continuing with the same patient, he responds rapidly to hydrocortisone with hemodynamic improvement. A trainee asks why his potassium was normal, unlike the hyperkalemia often taught for adrenal insufficiency. What is the best explanation?
A) His adrenal insufficiency is secondary, from suppression of the HPA (hypothalamic-pituitary-adrenal) axis by exogenous glucocorticoids, which reduces glucocorticoid output while sparing the renin-angiotensin-aldosterone-driven mineralocorticoid axis, so aldosterone-dependent potassium handling is preserved and hyperkalemia does not occur
B) Hyperkalemia was simply missed and would have appeared on repeat testing
C) Hydrocortisone has such strong mineralocorticoid activity that it corrected an existing hyperkalemia instantly before the first draw
D) His potassium was normal because secondary adrenal insufficiency causes hypokalemia, not normal potassium
E) The normal potassium proves he did not have adrenal insufficiency at all
ANSWER: A
Rationale:
In secondary adrenal insufficiency from HPA axis suppression, glucocorticoid output falls but the mineralocorticoid axis, driven mainly by renin-angiotensin-aldosterone rather than ACTH, is preserved, so aldosterone-dependent potassium handling continues and hyperkalemia does not develop, unlike in primary adrenal insufficiency where aldosterone is also lost. This makes Option A correct.
Option B: Option B is incorrect because the normal potassium reflects the preserved mineralocorticoid axis, not a missed value.
Option C: Option C is incorrect because the explanation is the preserved aldosterone axis, not instantaneous correction of hyperkalemia by hydrocortisone.
Option D: Option D is incorrect because secondary adrenal insufficiency characteristically leaves potassium normal rather than causing hypokalemia.
Option E: Option E is incorrect because the clinical course and response to hydrocortisone confirm adrenal crisis; a normal potassium is expected in the secondary form.
17. [CASE 5 — QUESTION 1]
A 55-year-old man with COPD (chronic obstructive pulmonary disease) and a 40-pack-year smoking history continues to smoke and reports a poor symptomatic response to inhaled corticosteroids despite confirmed good adherence and technique. Which mechanism best explains his reduced cellular response to corticosteroids?
A) Smoking saturates annexin-A1, leaving no further anti-inflammatory capacity for the drug
B) Smoking accelerates hepatic clearance of inhaled drug, so any dose is subtherapeutic
C) Smoking upregulates glucocorticoid receptors, causing receptor desensitization and tolerance
D) Smoking increases IkappaB-alpha, preventing the receptor from entering the nucleus
E) Oxidative stress from cigarette smoke inactivates histone deacetylase 2 (HDAC2) in airway macrophages, impairing the glucocorticoid receptor's recruitment of HDAC2 to switch off NF-kappaB-driven inflammatory genes, which reduces corticosteroid responsiveness at the cellular level
ANSWER: E
Rationale:
Glucocorticoid suppression of NF-kappaB-driven genes partly depends on the receptor recruiting histone deacetylase 2 (HDAC2) to close chromatin at those promoters. In smokers and in COPD, oxidative stress modifies and inactivates HDAC2 in airway macrophages, so the receptor cannot recruit functional HDAC2 and corticosteroid responsiveness falls; reducing oxidative stress through smoking cessation is central to restoring response. This makes Option E correct.
Option A: Option A is incorrect because smoke does not saturate annexin-A1 to render the drug ineffective; the defect is at HDAC2.
Option B: Option B is incorrect because the resistance is not explained by accelerated hepatic clearance.
Option C: Option C is incorrect because the mechanism is HDAC2 inactivation, not receptor upregulation with desensitization.
Option D: Option D is incorrect because increased IkappaB-alpha would reduce NF-kappaB activity and does not describe the smoke-related resistance mechanism.
18. [CASE 5 — QUESTION 2]
Continuing with the same patient, he is also prescribed an inhaled corticosteroid as part of a combination inhaler and asks how the drug can help his lungs without major whole-body steroid effects. Which pair of mechanisms underlies this pharmacokinetic dissociation?
A) High oral bioavailability with slow hepatic metabolism keeping levels high locally and systemically
B) Poor gastrointestinal absorption of the swallowed fraction together with extensive first-pass hepatic metabolism of absorbed drug, so high airway concentrations are achieved while little active drug reaches the systemic circulation
C) Rapid renal excretion of unchanged drug with negligible protein binding
D) Active transport of drug from the systemic circulation back into the airway
E) Conversion in the liver to a more systemically active metabolite
ANSWER: B
Rationale:
Inhaled corticosteroids achieve high local airway concentrations with limited systemic effect because the swallowed fraction is poorly absorbed from the gastrointestinal tract and the absorbed portion undergoes extensive first-pass hepatic metabolism, so little active drug reaches the systemic circulation. This makes Option B correct.
Option A: Option A is incorrect because high oral bioavailability with slow metabolism would raise systemic exposure, defeating the design.
Option C: Option C is incorrect because the dissociation depends on gut absorption and first-pass metabolism, not rapid renal excretion.
Option D: Option D is incorrect because there is no transporter returning systemic drug to the airway.
Option E: Option E is incorrect because conversion to a more systemically active metabolite would increase, not limit, systemic activity.
19. [CASE 5 — QUESTION 3]
Continuing with the same patient, his asthma-COPD overlap is poorly controlled and he is escalated to high-dose inhaled fluticasone propionate (greater than 500 micrograms per day). Which counseling about systemic risk is most accurate?
A) At any dose the first-pass effect is absolute, so there is no systemic risk to discuss
B) Systemic effects occur only if he swallows rather than inhales the dose
C) High-dose inhaled therapy produces more systemic effect than equivalent oral therapy because inhalation bypasses metabolism
D) At high doses the systemically available inhaled fraction becomes large enough to cause measurable effects such as HPA (hypothalamic-pituitary-adrenal) axis suppression, posterior subcapsular cataracts, and skin thinning, so the lowest effective dose with regular review is advised
E) High-dose inhaled corticosteroids cannot suppress the HPA axis under any circumstances
ANSWER: D
Rationale:
The favorable systemic profile of inhaled corticosteroids is dose-dependent: the inhaled fraction reaching the circulation is not removed by first-pass metabolism, and at high doses this fraction grows enough to cause measurable systemic effects, including HPA axis suppression, posterior subcapsular cataracts, and skin thinning, so the lowest effective dose with regular review is recommended. This makes Option D correct.
Option A: Option A is incorrect because the first-pass effect is not absolute and does not remove the directly absorbed inhaled fraction.
Option B: Option B is incorrect because systemic effects arise mainly from the inhaled fraction, not solely from swallowed drug.
Option C: Option C is incorrect because inhaled therapy generally produces less, not more, systemic effect than equivalent oral therapy.
Option E: Option E is incorrect because high-dose inhaled corticosteroids can suppress the HPA axis.
20. [CASE 5 — QUESTION 4]
Continuing with the same patient, his eosinophilic airway inflammation responds well to inhaled corticosteroid therapy. Which cellular mechanism best accounts for the efficacy of glucocorticoids in eosinophilic allergic airway disease?
A) Glucocorticoids increase eosinophil survival, flooding the airway with regulatory eosinophils
B) Glucocorticoids enhance mast cell mediator release to desensitize the airway
C) Glucocorticoids promote eosinophil apoptosis, reducing tissue eosinophil numbers, and reduce mast cell numbers and mediator release in part through suppression of stem cell factor (SCF), lowering histamine, cysteinyl leukotrienes, and prostaglandin D2 and thereby reducing bronchospasm, mucus, and vascular permeability
D) Glucocorticoids act only on neutrophils and have no effect on eosinophils or mast cells
E) Glucocorticoids increase IgE production to neutralize allergens
ANSWER: C
Rationale:
Glucocorticoids promote eosinophil apoptosis, rapidly reducing tissue eosinophil numbers, and they reduce mast cell numbers and impair their activation in part through suppression of stem cell factor (SCF), lowering release of histamine, cysteinyl leukotrienes, and prostaglandin D2; the result is reduced bronchospasm, mucus production, and vascular permeability in allergic airways disease. This makes Option C correct.
Option A: Option A is incorrect because glucocorticoids drive eosinophil apoptosis rather than increasing eosinophil survival.
Option B: Option B is incorrect because glucocorticoids reduce, not enhance, mast cell mediator release.
Option D: Option D is incorrect because eosinophils and mast cells are central targets of glucocorticoid action in allergic airway disease.
Option E: Option E is incorrect because glucocorticoids do not increase IgE production to neutralize allergens.
21. [CASE 6 — QUESTION 1]
A 27-year-old woman with systemic lupus erythematosus (SLE) is admitted with a severe lupus nephritis flare: rising serum creatinine, nephrotic-range proteinuria, and an active urinary sediment. Which induction approach to glucocorticoid therapy is most appropriate?
A) High-dose intravenous methylprednisolone pulse therapy followed by high-dose oral prednisone with a gradual taper, combined with a steroid-sparing immunosuppressant such as mycophenolate mofetil or cyclophosphamide to provide sustained organ-preserving control and allow the steroid to be tapered
B) Low-dose oral prednisone alone, tapered over one week
C) Hydroxychloroquine optimization alone without systemic glucocorticoids
D) An inhaled corticosteroid to limit systemic exposure
E) A superpotent topical corticosteroid for any rash, with no systemic therapy
ANSWER: A
Rationale:
Severe organ-threatening lupus such as active lupus nephritis warrants high-dose intravenous methylprednisolone pulse therapy followed by high-dose oral prednisone with a gradual taper, combined with a longer-acting immunosuppressant such as mycophenolate mofetil or cyclophosphamide that provides sustained disease control and allows the steroid to be tapered. This makes Option A correct.
Option B: Option B is incorrect because low-dose prednisone alone is inadequate for severe nephritis.
Option C: Option C is incorrect because hydroxychloroquine optimization suits mild mucocutaneous or musculoskeletal flares, not active severe nephritis.
Option D: Option D is incorrect because inhaled corticosteroids are airway-targeted and do not treat lupus nephritis.
Option E: Option E is incorrect because a topical agent addresses only skin disease and leaves the organ-threatening renal flare untreated.
22. [CASE 6 — QUESTION 2]
Continuing with the same patient, the team explains how the pulse glucocorticoid rapidly suppresses the autoimmune flare. Which mechanism best describes the principal acute immunosuppressive action on T lymphocytes?
A) Immediate complement-mediated lysis of all circulating T cells
B) Permanent clonal deletion of the peripheral T cell repertoire
C) Stimulation of IL-2 (interleukin-2) production to exhaust T cells
D) Rapid redistribution of T lymphocytes from the circulation into lymphoid tissues, together with suppression of IL-2 production that inhibits clonal expansion of activated T cells, dampening the autoantibody-mediated and cell-mediated injury
E) Selective expansion of cytotoxic T cells to clear autoreactive clones
ANSWER: D
Rationale:
Glucocorticoids acutely lower circulating T lymphocytes mainly by redistributing them from blood into lymphoid tissues, and they suppress IL-2 production, which is the key growth signal for clonal expansion of activated T cells; together these actions rapidly dampen the cell-mediated and autoantibody-driven tissue injury of a lupus flare. This makes Option D correct.
Option A: Option A is incorrect because the acute fall reflects redistribution rather than complement-mediated lysis.
Option B: Option B is incorrect because the effect is reversible and not permanent clonal deletion.
Option C: Option C is incorrect because glucocorticoids suppress, rather than stimulate, IL-2 production.
Option E: Option E is incorrect because glucocorticoids do not work by selectively expanding cytotoxic T cells.
23. [CASE 6 — QUESTION 3]
Continuing with the same patient, she will need a prolonged high-dose oral prednisone taper over months. Which statement best describes the bone effect to anticipate and its mechanism?
A) Net bone gain, because glucocorticoids stimulate osteoblast proliferation
B) Stable bone mass, because increased resorption is balanced by increased formation
C) An effect on osteoclasts only, leaving osteoblasts untouched
D) Complete cessation of bone turnover, so fracture risk does not change
E) Net bone loss, because glucocorticoids raise RANKL (receptor activator of nuclear factor kappa-B ligand) and lower OPG (osteoprotegerin) to favor osteoclast-driven resorption while suppressing osteoblast differentiation and promoting osteoblast apoptosis, supporting early glucocorticoid-induced osteoporosis prevention
ANSWER: E
Rationale:
Glucocorticoids increase RANKL and decrease OPG, favoring osteoclast-driven resorption, and simultaneously suppress osteoblast differentiation and promote osteoblast apoptosis, reducing formation. The combination produces net bone loss, which makes early attention to glucocorticoid-induced osteoporosis prevention appropriate during a prolonged high-dose course. This makes Option E correct.
Option A: Option A is incorrect because glucocorticoids reduce, not stimulate, bone formation.
Option B: Option B is incorrect because formation falls rather than balancing increased resorption.
Option C: Option C is incorrect because both osteoclasts and osteoblasts are affected.
Option D: Option D is incorrect because turnover is not halted; resorption is actively favored, raising fracture risk.
24. [CASE 6 — QUESTION 4]
Continuing with the same patient, a complete blood count drawn the day after pulse therapy shows neutrophilia, lymphopenia, monocytopenia, and a markedly suppressed eosinophil count. How should this pattern be interpreted?
A) It indicates a superimposed bacterial infection requiring empiric antibiotics
B) It is the expected pharmacological pattern of glucocorticoid therapy — neutrophilia from demargination and marrow release, lymphopenia and monocytopenia from redistribution, and eosinopenia reflecting active glucocorticoid receptor engagement — and requires reinterpreting the usual reference ranges rather than treating for infection
C) It indicates bone marrow failure and warrants stopping the glucocorticoid
D) It reflects a new allergic reaction to the immunosuppressant
E) It proves the glucocorticoid is not engaging its receptor
ANSWER: B
Rationale:
The combined pattern of neutrophilia, lymphopenia, monocytopenia, and eosinopenia is the expected pharmacological signature of glucocorticoid therapy: neutrophilia from demargination and marrow release, lymphopenia and monocytopenia from redistribution, and eosinopenia reflecting active receptor engagement. It should be read as drug effect, with reference ranges reinterpreted accordingly, rather than as infection. This makes Option B correct.
Option A: Option A is incorrect because this is the predictable drug pattern, not evidence of bacterial infection.
Option C: Option C is incorrect because the changes reflect redistribution and apoptosis from drug effect, not marrow failure.
Option D: Option D is incorrect because eosinopenia reflects glucocorticoid effect rather than a new allergic reaction, which would tend to raise eosinophils.
Option E: Option E is incorrect because the suppressed eosinophil count indicates active, not absent, receptor engagement.
25. [CASE 7 — QUESTION 1]
A 60-year-old man with metastatic lung cancer presents with progressive headache, nausea, and a new focal neurological deficit. Imaging shows a brain metastasis with extensive peritumoral vasogenic edema. Which glucocorticoid is preferred, and why?
A) Hydrocortisone, because its mineralocorticoid activity supports cerebral perfusion
B) Fludrocortisone, because mineralocorticoid effects reduce vasogenic edema
C) Dexamethasone, because its high glucocorticoid potency, negligible mineralocorticoid activity that avoids worsening fluid retention, and long duration of action suit this setting, and it reduces VEGF (vascular endothelial growth factor)-driven vascular permeability that drives the edema
D) An inhaled corticosteroid, to minimize systemic exposure
E) A superpotent topical corticosteroid applied to the scalp over the lesion
ANSWER: C
Rationale:
Dexamethasone is the preferred agent for peritumoral vasogenic edema because of its high glucocorticoid potency, negligible mineralocorticoid activity (avoiding added sodium and water retention in a patient at risk of raised intracranial pressure), and long duration of action, and mechanistically it reduces VEGF-driven vascular hyperpermeability that fuels the edema. This makes Option C correct.
Option A: Option A is incorrect because hydrocortisone's mineralocorticoid activity is undesirable here.
Option B: Option B is incorrect because fludrocortisone is a mineralocorticoid that would promote fluid retention rather than reduce edema.
Option D: Option D is incorrect because inhaled corticosteroids are airway-targeted and do not treat cerebral edema.
Option E: Option E is incorrect because a topical scalp corticosteroid cannot reach intracranial peritumoral edema.
26. [CASE 7 — QUESTION 2]
Continuing with the same patient, dexamethasone is initiated for the cerebral edema. Which dosing approach is most consistent with standard management of symptomatic peritumoral edema?
A) Dexamethasone administered at approximately 4 to 16 milligrams per day in divided doses, titrated to symptom severity and neurological status
B) A single 1 milligram dose given once, with no further therapy
C) Continuous high-dose mineralocorticoid infusion
D) Inhaled dexamethasone four times daily
E) Topical dexamethasone applied to the scalp twice daily
ANSWER: A
Rationale:
Dexamethasone for symptomatic peritumoral cerebral edema is typically given at about 4 to 16 milligrams per day in divided doses, with the dose adjusted to the severity of symptoms and neurological status. This matches standard management, making Option A correct.
Option B: Option B is incorrect because a single 1 milligram dose is inadequate for symptomatic peritumoral edema.
Option C: Option C is incorrect because the treatment is a glucocorticoid such as dexamethasone, not a continuous mineralocorticoid infusion.
Option D: Option D is incorrect because inhaled dexamethasone is airway-targeted and does not treat cerebral edema.
Option E: Option E is incorrect because topical scalp application cannot reach intracranial edema.
27. [CASE 7 — QUESTION 3]
Continuing with the same patient, during his hospitalization he develops fever, neck stiffness, and altered mental status, and bacterial meningitis is suspected. The team prepares empiric antibiotics and considers adjunctive dexamethasone. Regarding timing, which instruction is correct?
A) Give dexamethasone only if he fails to improve after 48 hours of antibiotics
B) Give dexamethasone with or immediately before the first antibiotic dose, because blunting the inflammatory surge that follows antibiotic-induced bacterial lysis is what reduces severe neurological sequelae
C) Give dexamethasone several days later once cultures return
D) Withhold dexamethasone entirely, since glucocorticoids are contraindicated in central nervous system infection
E) Give dexamethasone only after the inflammatory response has fully resolved
ANSWER: B
Rationale:
Adjunctive dexamethasone reduces severe neurological sequelae in bacterial meningitis by blunting the intense subarachnoid inflammatory response triggered when antibiotics lyse bacteria; the benefit depends on the drug being present with or immediately before the first antibiotic dose. This makes Option B correct.
Option A: Option A is incorrect because waiting 48 hours misses the inflammatory surge that accompanies initial bacterial killing.
Option C: Option C is incorrect because delaying until cultures return forfeits the critical timing window.
Option D: Option D is incorrect because adjunctive dexamethasone is beneficial rather than contraindicated in bacterial meningitis.
Option E: Option E is incorrect because giving it after inflammation has resolved provides no protection against the early lysis-driven injury.
28. [CASE 7 — QUESTION 4]
Continuing with the same patient, a trainee notes that dexamethasone was the chosen glucocorticoid for both the peritumoral cerebral edema and the bacterial meningitis. Integrating its properties, why is dexamethasone well suited to both central nervous system settings?
A) Its strong mineralocorticoid activity promotes the sodium retention needed for cerebral perfusion in both conditions
B) Its short duration allows rapid clearance, which is the reason it is chosen in both settings
C) Its low potency requires large doses that improve drug delivery to the brain
D) Its high glucocorticoid potency, negligible mineralocorticoid activity that avoids aggravating fluid retention and raised intracranial pressure, and long duration of action permitting convenient dosing make it appropriate across both central nervous system indications
E) It is selected only by institutional habit, with no pharmacological basis
ANSWER: D
Rationale:
Dexamethasone suits both central nervous system settings because it combines high glucocorticoid potency, negligible mineralocorticoid activity (so it does not aggravate fluid retention or raised intracranial pressure), and a long duration of action that permits convenient dosing; these shared properties explain its selection for peritumoral edema and for adjunctive use in bacterial meningitis. This makes Option D correct.
Option A: Option A is incorrect because dexamethasone has negligible, not strong, mineralocorticoid activity, and avoiding fluid retention is part of why it is chosen.
Option B: Option B is incorrect because dexamethasone is long-acting rather than rapidly cleared.
Option C: Option C is incorrect because dexamethasone is high-potency and is not chosen because of large-volume dosing.
Option E: Option E is incorrect because the choice rests on clear pharmacological properties rather than habit.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.